AstraZeneca PLC is 21.7x more valuable than BridgeBio Pharma, Inc. by market capitalization ($286.27 B vs $13.20 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BBIO | AZN |
|---|---|---|
| Market cap | $13.20 B | $286.27 B |
| US-listed rank | #791 | #45 |
| Revenue (latest FY) | $502.08M | - |
| SEC filings | 777 | 1,004 |
AstraZeneca PLC is 21.7x more valuable than BridgeBio Pharma, Inc. by market capitalization ($286.27 B vs $13.20 B).
Full pages: BridgeBio Pharma, Inc. and AstraZeneca PLC, or browse the full rankings.